Top Core and Group Health Stories
Wegovy and other GLP-1s curb demand for bariatric surgery: JAMA study
By Allison BellAbout 6% of Americans with obesity and without diabetes have had surgery or taken GLP-1 agonists, the research team estimates.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
About 6% of Americans with obesity and without diabetes have had surgery or taken GLP-1 agonists, the research team estimates.